Transaction overview
On January 26, 2015, Thompson Street Capital Partners (TSCP) acquired a majority stake in Infinity Behavioral Health Services (IBHS), an American provider of revenue cycle management services for the behavioral health sector. The financial details of the deal were not disclosed at the time of acquisition and have remained undisclosed since. IBHS offers a comprehensive suite of front-end to back-end billing solutions, customizable reporting capabilities, and business consulting services tailored to the unique needs of the behavioral health market.
Deal structure and financing
The precise equity and debt composition used in funding the acquisition was not made public at the time or subsequently revealed. As no financial details were disclosed, information on lead banks involved and leverage metrics remains unknown. However, considering TSCP's strategy of investing in middle-market companies with $5 million to $100 million in enterprise value, it is likely that a combination of debt financing from institutional lenders and equity investment from private sources was utilized.
Strategic context
TSCP’s acquisition of IBHS represented an opportunity for the firm to enter the behavioral health revenue cycle management market. The deal allowed TSCP to leverage its expertise in building scalable business operations within healthcare services while addressing the specific challenges faced by providers in managing complex payment processes. For IBHS, being part of a private equity portfolio potentially opened up avenues for scaling operations and expanding service offerings through strategic acquisitions, such as Health Assets Management and Hyperion Billing Solutions.
IBHS's decision to sell back to TSCP in 2022 indicates that the firm successfully grew its market position under private ownership. This exit strategy aligns with TSCP’s approach of realizing investments after five to seven years, often through sale transactions or recapitalizations rather than initial public offerings (IPOs). The exact terms of this second transaction remain undisclosed but suggest a successful period marked by operational improvements and revenue growth.
Regulatory path
The acquisition did not require regulatory review given the nature of the healthcare services market and the relatively small size of IBHS at the time of acquisition. As no specific jurisdictions or regulators were involved in reviewing this deal, it is presumed that standard due diligence practices were sufficient to ensure compliance with local laws and regulations governing acquisitions in the healthcare sector.
The timeline for HSR filings or EU regulatory reviews was not applicable, as the transaction fell below thresholds requiring antitrust scrutiny by federal agencies such as the Federal Trade Commission (FTC) or the Department of Justice (DOJ). Thus, TSCP could proceed without significant delays due to regulatory oversight.